Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VERVE-201 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose Escalation for Participants with Refractory Hypercholesterolemia | EXPERIMENTAL | Participants assigned to a dose-escalation cohort will receive a single dose of VERVE-201. |
| Part B: Re-Dosing for Part A Participants | EXPERIMENTAL | Participants from Part A assigned to the re-dosing cohort will receive a second dose of VERVE-201. |
| Part C: Single Ascending Dose Escalation for Participants with sHTG | EXPERIMENTAL | Participants assigned to a dose-expansion cohort will receive a single dose of VERVE-201. |
| Name | Type | Description |
|---|---|---|
| VERVE-201 | DRUG | Intravenous (IV) infusion |
Inclusion Criteria: * Refractory hypercholesterolemia * Refractory hypertriglyceridemia Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe * Clinically significant or abnorma...
Top 13 of 17 competitors
VERVE-201 is an investigational small molecule developed by Verve Therapeutics for hypercholesterolemia. It is designed to act on ANGPTL3 and is being studied in a Phase 1b trial in patients with refractory hyperlipidemia, a condition in which cholesterol and triglyceride levels remain elevated despite treatment.
VERVE-201 targets ANGPTL3, also known as angiopoietin-like protein 3. ANGPTL3 is a molecular target relevant to lipid metabolism, and VERVE-201 is a small molecule designed to act on it. The compound is being developed for hypercholesterolemia and related lipid disorders.
VERVE-201 is being developed by Verve Therapeutics, Inc., which trades under the ticker VERV. The company is running the Phase 1b program for the drug in patients with refractory hyperlipidemia across sites in the United States, Australia, Canada, the Netherlands, South Africa, and the United Kingdom.
VERVE-201 is in Phase 1 development. It is investigational and is being evaluated in a Phase 1b study in patients with refractory hyperlipidemia. No Phase 2 or later-stage trial of VERVE-201 is listed, and the program remains in clinical development.
VERVE-201 is being studied in the Phase 1b trial NCT06451770, titled a Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia. The trial is recruiting and plans to enroll 132 participants aged 18 years and older, with conditions including hypercholesterolemia, hypertriglyceridemia, and refractory hyperlipidemia.
VERVE-201 is being developed for hypercholesterolemia, specifically for patients with refractory hyperlipidemia whose lipid levels remain elevated. The Phase 1b trial NCT06451770 also enrolls patients with hypertriglyceridemia. VERVE-201 is investigational and has not been established as a treatment outside clinical research.